CA2375196A1 - Utilisation de gabapentine dans des analyses destinees a identifier des effecteurs du recepteur gabab - Google Patents

Utilisation de gabapentine dans des analyses destinees a identifier des effecteurs du recepteur gabab Download PDF

Info

Publication number
CA2375196A1
CA2375196A1 CA002375196A CA2375196A CA2375196A1 CA 2375196 A1 CA2375196 A1 CA 2375196A1 CA 002375196 A CA002375196 A CA 002375196A CA 2375196 A CA2375196 A CA 2375196A CA 2375196 A1 CA2375196 A1 CA 2375196A1
Authority
CA
Canada
Prior art keywords
seq
gaba
cells
positions
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002375196A
Other languages
English (en)
Inventor
Gordon Ng
Gary O'neill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Frosst Canada and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2375196A1 publication Critical patent/CA2375196A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9426—GABA, i.e. gamma-amino-butyrate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention se rapporte à l'utilisation de gabapentine dans de nouvelles analyses destinées à l'identification d'agonistes, d'agonistes inverses, d'antagonistes et d'effecteurs allostériques du récepteur GABA¿B?, dans lesquelles le récepteur fonctionnel de GABA¿B? provient de la co-expression de HG20 et GABA¿B?R1a or GABA¿B?R1b et de la formation d'hétérodimères de sous-unités de HG20 et GABA¿B?R1a ou GABA¿B?R1b.
CA002375196A 1999-06-01 2000-05-30 Utilisation de gabapentine dans des analyses destinees a identifier des effecteurs du recepteur gabab Abandoned CA2375196A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13702599P 1999-06-01 1999-06-01
US60/137,025 1999-06-01
PCT/CA2000/000638 WO2000073788A1 (fr) 1999-06-01 2000-05-30 Utilisation de gabapentine dans des analyses destinees a identifier des effecteurs du recepteur gaba¿b?

Publications (1)

Publication Number Publication Date
CA2375196A1 true CA2375196A1 (fr) 2000-12-07

Family

ID=22475482

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002375196A Abandoned CA2375196A1 (fr) 1999-06-01 2000-05-30 Utilisation de gabapentine dans des analyses destinees a identifier des effecteurs du recepteur gabab

Country Status (5)

Country Link
EP (1) EP1188056A1 (fr)
JP (1) JP2003501052A (fr)
AU (1) AU4907300A (fr)
CA (1) CA2375196A1 (fr)
WO (1) WO2000073788A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1297341A2 (fr) * 2000-06-19 2003-04-02 Merck Frosst Canada Inc. Techniques d'identification d'antagonistes specifiques de sous type de recepteurs gabab
FR2827045B1 (fr) * 2001-07-05 2007-08-10 Univ Pasteur Methodes et compositions pour la selection et le developpement de nouveaux agents pharmacologiques ou de nouveaux medicaments
KR20060120612A (ko) * 2003-09-12 2006-11-27 얀센 파마슈티카 엔.브이. 키메라 ｇａｂａｂ 수용체
EP3009513A1 (fr) * 2008-02-01 2016-04-20 Chromocell Corporation Nouvelles lignées cellulaires et procédés

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854002A (en) * 1996-12-17 1998-12-29 Rhone Poulenc, Inc. Method of identifying compounds that bind to the insect gaba receptor
WO1999040114A1 (fr) * 1998-02-05 1999-08-12 Merck & Co., Inc. Nouvelles sequences d'adn codant le recepteur gaba¿b?

Also Published As

Publication number Publication date
JP2003501052A (ja) 2003-01-14
AU4907300A (en) 2000-12-18
WO2000073788A1 (fr) 2000-12-07
EP1188056A1 (fr) 2002-03-20

Similar Documents

Publication Publication Date Title
EP0701611B1 (fr) Recepteurs humains du glutamate metabotropique, acides nucleiques codant ceux-ci et leurs utilisations
Maqueira et al. Identification and characterization of a novel family of Drosophilaβ‐adrenergic‐like octopamine G‐protein coupled receptors
WO1999040126A9 (fr) Catalyseur pour la (co)polymerisation de l'ethylene et son procede d'obtention
EP1560915A2 (fr) Methodes de dosage d'agonistes/antagonistes de canaux calciques selon l'etat
US5807689A (en) Methods for identifying compounds that modulate metabotropic glutamate receptor activity
US6362316B1 (en) Human metabotropic glutamate receptor subtype mGluR6 protein
US6534287B1 (en) Human metabotropic glutamate receptor
Polit et al. The Gαi protein subclass selectivity to the dopamine D 2 receptor is also decided by their location at the cell membrane
Hunter et al. Real-time measurement of cannabinoid receptor-mediated cAMP signaling
CA2321193A1 (fr) Nouvelles sequences d'adn codant le recepteur gabab
CA2375196A1 (fr) Utilisation de gabapentine dans des analyses destinees a identifier des effecteurs du recepteur gabab
Jones et al. Signal transduction by GABAB receptor heterodimers
Cotecchia Constitutive activity and inverse agonism at the α1adrenoceptors
AU2007267546B2 (en) Methods of screening for TRPM4 modulators of insulin secretion
Jacobson et al. High-Throughput Ca2+ Flux Assay To Monitor Cyclic Nucleotide-Gated Channel Activity and Characterize Achromatopsia Mutant Channel Function
WO2001098779A2 (fr) Techniques d'identification d'antagonistes specifiques de sous type de recepteurs gabab
WO2001017958A2 (fr) Dosages du recepteur de neuropeptide sf, composes et procedes therapeutiques
WO2001090141A2 (fr) Nouvelle isoforme gb1c et nucleotides codant pour celle-ci
AU2002318780B2 (en) Human Metabotropic Glutamate Receptor Subtype mGluR6
US20060281117A1 (en) Alternatively spliced isoform of calcium channel, voltage dependent, alpha-1G subunit (CACNA1G)
AU2006241365A1 (en) Human metabotropic glutamate receptor subtype mGluR6

Legal Events

Date Code Title Description
FZDE Dead